Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pancreatitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape. Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pancreatitis - Overview Pancreatitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Pancreatitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Pancreatitis - Companies Involved in Therapeutics Development Angion Biomedica Corp Bharat Serums And Vaccines Ltd CalciMedica Inc Cypralis Ltd Dynavax Technologies Corp Generon (Shanghai) Corp Ltd GlaxoSmithKline Plc LipimetiX Development Inc Novartis AG Pharming Group NV Sarfez Pharmaceuticals Inc Sun BioPharma Inc Takeda Pharmaceutical Company Ltd Pancreatitis - Drug Profiles AAD-2004 - Drug Profile Product Description Mechanism Of Action R&D Progress AEM-2802 - Drug Profile Product Description Mechanism Of Action R&D Progress AEM-2814 - Drug Profile Product Description Mechanism Of Action R&D Progress ANG-3070 - Drug Profile Product Description Mechanism Of Action R&D Progress C1 esterase inhibitor (recombinant) - Drug Profile Product Description Mechanism Of Action R&D Progress CM-128 - Drug Profile Product Description Mechanism Of Action R&D Progress CM-4620 - Drug Profile Product Description Mechanism Of Action R&D Progress DV-1179 - Drug Profile Product Description Mechanism Of Action R&D Progress F-652 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-180 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2795039 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-3335065 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-428 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-6288B - Drug Profile Product Description Mechanism Of Action R&D Progress P-2pal18S - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptides to Agonize RNLS for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile Product Description Mechanism Of Action R&D Progress SBP-101 - Drug Profile Product Description Mechanism Of Action R&D Progress SBP-102 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile Product Description Mechanism Of Action R&D Progress SP-20201 - Drug Profile Product Description Mechanism Of Action R&D Progress TAK-671 - Drug Profile Product Description Mechanism Of Action R&D Progress ulinastatin - Drug Profile Product Description Mechanism Of Action R&D Progress Withaferin A - Drug Profile Product Description Mechanism Of Action R&D Progress Pancreatitis - Dormant Projects Pancreatitis - Discontinued Products Pancreatitis - Product Development Milestones Featured News & Press Releases Aug 10, 2017: Sun BioPharma Provides Clinical Update May 24, 2017: CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Pancreatitis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2017 Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H2 2017 Pancreatitis - Pipeline by CalciMedica Inc, H2 2017 Pancreatitis - Pipeline by Cypralis Ltd, H2 2017 Pancreatitis - Pipeline by Dynavax Technologies Corp, H2 2017 Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017 Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2017 Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2017 Pancreatitis - Pipeline by Novartis AG, H2 2017 Pancreatitis - Pipeline by Pharming Group NV, H2 2017 Pancreatitis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 Pancreatitis - Pipeline by Sun BioPharma Inc, H2 2017 Pancreatitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Pancreatitis - Dormant Projects, H2 2017 Pancreatitis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
